Zhejiang Shapuaisi pharmaceutical announced that the company recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for Tobramycin Eye Drops. This pharmaceutical is used for local anti-infective treatment of sensitive strains of external eye and accessory infections. In August 2023, the company received the notification letter for the acceptance of this pharmaceutical, with a cumulative research and development investment of approximately 3.8162 million yuan. Obtaining the pharmaceutical registration certificate will enrich the company's product categories, help optimize product layout, but the future production and sales of the pharmaceutical are subject to multiple factors, and there is uncertainty regarding its performance impact.